Ryan J. Sullivan

4.6k total citations · 1 hit paper
30 papers, 1.3k citations indexed

About

Ryan J. Sullivan is a scholar working on Biomedical Engineering, Molecular Biology and Oncology. According to data from OpenAlex, Ryan J. Sullivan has authored 30 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Biomedical Engineering, 7 papers in Molecular Biology and 7 papers in Oncology. Recurrent topics in Ryan J. Sullivan's work include Innovative Microfluidic and Catalytic Techniques Innovation (5 papers), Stock Market Forecasting Methods (5 papers) and Cancer Immunotherapy and Biomarkers (5 papers). Ryan J. Sullivan is often cited by papers focused on Innovative Microfluidic and Catalytic Techniques Innovation (5 papers), Stock Market Forecasting Methods (5 papers) and Cancer Immunotherapy and Biomarkers (5 papers). Ryan J. Sullivan collaborates with scholars based in United States, Canada and United Kingdom. Ryan J. Sullivan's co-authors include Allan Timmermann, Halbert White, Stephen G. Newman, Marcel Schlaf, Jeanne Masson‐Makdissi, D.V. Soldatov, Mads P. Sulbæk Andersen, Gary J. Umphrey, Andrew D. Sutton and Cameron M. Moore and has published in prestigious journals such as Angewandte Chemie International Edition, Journal of Clinical Oncology and The Journal of Finance.

In The Last Decade

Ryan J. Sullivan

24 papers receiving 1.3k citations

Hit Papers

Data‐Snooping, Technical Trading Rule Performance, and th... 1999 2026 2008 2017 1999 200 400 600

Peers

Ryan J. Sullivan
Kwangwon Ahn South Korea
Yufeng Han United States
Biao Lu United States
In Ho Lee South Korea
Rui Huo China
Joonghyuk Kim South Korea
Ryan J. Sullivan
Citations per year, relative to Ryan J. Sullivan Ryan J. Sullivan (= 1×) peers Daniel Rösch

Countries citing papers authored by Ryan J. Sullivan

Since Specialization
Citations

This map shows the geographic impact of Ryan J. Sullivan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ryan J. Sullivan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ryan J. Sullivan more than expected).

Fields of papers citing papers by Ryan J. Sullivan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ryan J. Sullivan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ryan J. Sullivan. The network helps show where Ryan J. Sullivan may publish in the future.

Co-authorship network of co-authors of Ryan J. Sullivan

This figure shows the co-authorship network connecting the top 25 collaborators of Ryan J. Sullivan. A scholar is included among the top collaborators of Ryan J. Sullivan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ryan J. Sullivan. Ryan J. Sullivan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Sullivan, Ryan J., Katy K. Tsai, Anna C. Pavlick, et al.. (2025). Phase 1b Study of Tovorafenib, Plozalizumab or Vedolizumab Plus Standard-of-Care Immune Checkpoint Inhibitors in Patients with Advanced Melanoma. Journal of Cancer. 16(13). 3797–3809.
3.
Lee, Johnny W., Melissa Lee, Liam S. Sharninghausen, et al.. (2025). A Second-Generation Route to the Cereblon Fragment of ARV-471, Vepdegestrant. Organic Process Research & Development. 29(11). 2636–2648.
4.
Sullivan, Ryan J., et al.. (2025). KIT-Mutant Melanoma: Understanding the Pathway to Personalized Therapy. Cancers. 17(22). 3644–3644.
5.
Sullivan, Ryan J., J.C. Hassel, Teresa Amaral, et al.. (2025). 954P A randomized phase II study of autogene cevumeran plus pembrolizumab (pembro) versus pembro in 1L advanced melanoma (IMcode001). Annals of Oncology. 36. S585–S585.
6.
Poudel, Kishwor, Zhenyu Ji, Ching-Ni Jenny Njauw, et al.. (2024). Fabrication and functional validation of a hybrid biomimetic nanovaccine (HBNV) against Kit-mutant melanoma. Bioactive Materials. 46. 347–364. 2 indexed citations
7.
Sullivan, Ryan J., Taegyo Lee, Brian P. Jones, et al.. (2024). General and Scalable Synthesis of 2-Aryl and 2-Alkyl Pyrimidines via an Electronically Tuned SNAr Approach. Organic Letters. 26(22). 4626–4630. 1 indexed citations
8.
Warner, Allison Betof, James W. Smithy, Nathan Hasson, et al.. (2024). 1102P Immune checkpoint inhibitor rechallenge after treatment with tumor-infiltrating lymphocytes in unresectable melanoma. Annals of Oncology. 35. S730–S731. 2 indexed citations
9.
Sheng‐Kai, Kevin, Cho‐Hung Chiang, Thomas E. Van Dyke, et al.. (2024). Periodontitis is an immune-related adverse event associated with immune checkpoint inhibitors: A multi-center cohort study. Cancer Letters. 598. 217100–217100. 6 indexed citations
10.
Bell, David A., et al.. (2024). A continuous mode of action of nitric oxide in hard-to-heal wound healing. Journal of Wound Care. 33(12). 912–925. 2 indexed citations
11.
Leung, Bonnie W., Guihong Wan, Wenxin Chen, et al.. (2023). Increased risk of cutaneous immune-related adverse events in patients treated with talimogene laherparepvec and immune checkpoint inhibitors: A multi-hospital cohort study. Journal of the American Academy of Dermatology. 88(6). 1265–1270. 3 indexed citations
13.
Sullivan, Ryan J., et al.. (2019). Synthesis and characterization of novel tetradentate ruthenium complexes of a pyridine-o-phenylenediamine based chelate ligand. Inorganica Chimica Acta. 502. 119391–119391.
14.
Sullivan, Ryan J. & Stephen G. Newman. (2018). Chiral auxiliary recycling in continuous flow: automated recovery and reuse of Oppolzer's sultam. Chemical Science. 9(8). 2130–2134. 7 indexed citations
15.
Sullivan, Ryan J., et al.. (2018). Hochdurchsatzstrategien zur Entdeckung und Optimierung katalytischer Reaktionen. Angewandte Chemie. 131(22). 7254–7267. 13 indexed citations
16.
Sullivan, Ryan J., Allan Timmermann, & Halbert White. (2002). Forecast evaluation with shared data sets. International Journal of Forecasting. 19(2). 217–227. 4 indexed citations
17.
Sullivan, Ryan J., Allan Timmermann, & Halbert White. (2001). Dangers of data mining: The case of calendar effects in stock returns. Journal of Econometrics. 105(1). 249–286. 202 indexed citations
18.
Sullivan, Ryan J., Allan Timmermann, & Halbert White. (1999). Data‐Snooping, Technical Trading Rule Performance, and the Bootstrap. The Journal of Finance. 54(5). 1647–1691. 707 indexed citations breakdown →
19.
Sullivan, Ryan J., Allan Timmermann, & Halbert White. (1998). Dangers of Data-Driven Inference: The Case of Calendar Effects in Stock Returns. eScholarship (California Digital Library). 36 indexed citations
20.
Sullivan, Ryan J., Allan Timmermann, & Halbert White. (1997). Data-Snooping, Technical Trading Rule Performance, and the Bootstrap. London School of Economics and Political Science Research Online (London School of Economics and Political Science). 57 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026